Department of Respiratory & Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
Biomark Med. 2021 Apr;15(6):427-436. doi: 10.2217/bmm-2020-0566. Epub 2021 Mar 12.
Long noncoding RNA (lncRNA) noncoding RNA activated by DNA damage (NORAD) is widely investigated in different tumors. Our meta-analysis intends to assess the prognostic and clinicopathological value of NORAD in cancers. We searched PubMed, Web of Science, Embase and Chinese National Knowledge Infrastructure from inception to 1 August 2020. The results showed that higher expression of NORAD had a significant association with worse overall survival. Additionally, correlations were detected between elevated level of NORAD and poor differentiation degree, positive lymph node metastasis and large tumor size in cancer patients. LncRNA NORAD can serve as a novel and promising biomarker for prognosis and clinicopathological characteristics in different cancers.
长链非编码 RNA（lncRNA）DNA 损伤激活的非编码 RNA（NORAD）在不同的肿瘤中被广泛研究。我们的荟萃分析旨在评估 NORAD 在癌症中的预后和临床病理价值。我们从建库到 2020 年 8 月 1 日在 PubMed、Web of Science、Embase 和中国国家知识基础设施中进行了检索。结果表明，NORAD 的高表达与总生存期较差有显著相关性。此外，在癌症患者中，NORAD 水平升高与分化程度差、淋巴结转移阳性和肿瘤较大有关。lncRNA NORAD 可以作为不同癌症中预后和临床病理特征的新型有前途的生物标志物。
